Joel Parker

Joel Parker, PhD, is an Adjunct Associate Professor in the Department of Genetics at the UNC School of Medicine, University of North Carolina at Chapel Hill. His research focuses on cancer genomics, particularly in breast cancer subtyping, biomarker development, and precision medicine. He leads studies on genetic and transcriptomic profiling to predict treatment responses and clinical outcomes in oncology. His work integrates liquid biopsy technologies, immune signatures, and genomic assays like HER2DX and TNBC-DX to improve diagnostic and therapeutic strategies.

Key research areas include:

• Genetic drivers of therapeutic resistance in breast cancer
• Single-cell epigenetic and transcriptomic analysis of tumor heterogeneity
• Multimodal biomarker validation for personalized cancer care
• Immune microenvironment correlates in tumor progression

Recent publications (2024-2025) emphasize:

• Validation of HER2DX and TNBC-DX genomic assays in clinical trials
• Plasma-based prediction of metastatic breast cancer outcomes
• Epigenetic mechanisms in melanoma and lymphoma
• Racial disparities in basal-like breast cancer prognosis

Collaborations include the Sweden Cancerome Analysis Network (SCAN-B) and trials like NeoALTTO and TNT. No specific grants or awards are explicitly listed, though his work aligns with UNC’s broader oncology research initiatives.